Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

U.S. stocks performed positively again this week as investors assessed a flood of corporate earnings and the latest news ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7%, driven by growth across all ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its ...